Figure 1.
A proposed approach for treatment of newly diagnosed non-DLBCL monomorphic PTLDs of B-cell origin and cHL-PTLD. ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; AVD, doxorubicin, vinblastine, and dacarbazine; BTK, Bruton tyrosine kinase.

A proposed approach for treatment of newly diagnosed non-DLBCL monomorphic PTLDs of B-cell origin and cHL-PTLD. ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; AVD, doxorubicin, vinblastine, and dacarbazine; BTK, Bruton tyrosine kinase.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal